The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Patients with stage IIA and IIB esophageal squamous cell carcinoma (ESCC) with ...
The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection. The agency also expanded the indication for ...
PITTSBURGH, Sept. 18, 2021 – An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma, according to the results of an international, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback